> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Extends Comment Period in Intended Use Rule
- URL: https://www.fdaweb.com/fda-extends-comment-period-in-intended-use-rule/
- Published: 2017-05-18T12:00:00.000Z
- Updated: 2026-09-14T22:24:23.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138731

*Federal Register* notice: FDA has extended until 7/18 the comment period on a final rule that clarifies for drug and device manufacturers the agency’s interpretation and application of its existing definitions of “intended use” ([see earlier story](https://www.fdaweb.com/will-trump-administration-scrap-intended-use-new-rule/)). The comment extension is related to a citizen petition from medical product groups ([see story](https://www.fdaweb.com/stakeholders-ask-intended-use-rule-stay-and-reconsideration/)) that sought an indefinite stay of the rule. The [petition](https://www.regulations.gov/contentStreamer?documentId=FDA-2016-N-1149-0048&attachmentNumber=1&disposition=attachment&contentType=pdf&ref=fdaweb.com) said that agency staff should be directed to promulgate final definitions of intended use that are consistent with the proposed definitions set out in a 9/25/15 notice of proposed rulemaking. FDA has already announced delayed implementation of the 1/9 rule to give the Trump administration time to consider what it wants to do with it. To view the notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2017-05-18/pdf/2017-10036.pdf?ref=fdaweb.com)